Rhythm’s Setmelanotide Loses Fast-Track Status In Europe
Product Reverts To Standard Review; US Approval Decision Due This Month
The loss of fast-track status for setmelanotide at the European Medicines Agency means the review of the potential treatment of two rare genetic disorders of obesity will take longer than Rhythm Pharmaceuticals had originally hoped.
